Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Marsh & McLennan Companies, Inc. — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Marsh & McLennan Companies, Inc. trades at $179.94 (market cap $84.47B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 2.7× GE HealthCare Technologies Inc. Common Stock's market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.24%). Which is the better fit depends on your goals.
| GEHC | MRSH | |
|---|---|---|
Market Cap | $31.07B | $84.47B |
Volume | 3,443,020 | 3,662,234 |
Sector | Health | Financials |
52-Week High | $88.16 | $203.85 |
52-Week Low | $59.48 | $157.32 |
Enterprise Value | $39.53B | $105.15B |
Dividend Yield | 0.23% | 2.24% |
Typical Hold Time | — | 109 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Marsh (MRSH) trades at $178.40, up 1.05% today, with a bullish technical signal and recent earnings beats. The stock shows strong fundamentals with a P/E of 21.61, net income margin of 14.24%, and consistent revenue growth to $27.0B in 2025. Recent acquisition of Accel Holdings (Business Wire, 2026-10-02) enhances its advisory services, while analyst consensus is a 'Hold' with a $202.71 price target. Cash flow remains positive at $486M in 2025, supporting dividend payments.
Outlook is cautiously optimistic; the stock offers growth potential from strategic acquisitions and solid profitability, but risks include high P/B of 5.56 and competitive pressures. Investors should weigh the 13.6% upside to the consensus target against overbought RSI levels and margin compression risks in 2026 forecasts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
